Acne Drugs Market Size, Share & Analysis Report, 2023-2032
The global acne drugs market size was exhibited at USD 6.51 billion in 2022 and is projected to hit around USD 15.69 billion by 2032, growing at a CAGR of 9.2% during the forecast period 2023 to 2032.
Key Pointers:
Acne Drugs Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 7.1 Billion |
| Market Size by 2032 | USD 15.69 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 9.2% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Type, Therapeutic Class, Mode of Administration |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Allergan Plc, AndroScience, Anterios, Aqua Pharmaceuticals, Bayer HealthCare, Cipher Pharmaceuticals Galderma S.A., GlaxoSmithKline Plc (Stiefel Laboratories, Inc.), Johnson & Johnson, Mayne Pharma Group Limited, Mylan N.V., Nestlé S.A. (Galderma S.A.), Oculus Innovative Sciences, Pfizer Inc. |
Several factors such as emergence of biologics, unhealthy lifestyle, and rising disease incidence are anticipated to drive the market.
Acne vulgaris is one of the most common dermatological disorders, affecting 9.4% people worldwide. Although the condition can affect people of all ages, it is most prevalent among teenagers. It has been found that the condition is prevalent in more than 85.0% people between the ages of 12 and 25. Acne can appear in forms ranging from comedones to cystic lesions, depending on its severity.
Retinoids and antibiotics remain the mainstays of acne treatment. Retinoids led the therapeutic classes in 2022, and it is expected to continue this trend through 2032. The therapeutic landscape is witnessing a shift toward combination treatment due to higher efficacy, convenient dosing, and fewer adverse effects.
By mode of administration, topical drugs currently dominate the market. Severe cases see the use of systemic medications such as oral antibiotics, hormonal agents, or other drugs. However, emergence of biologics (Gevokizumab and RA-18C3) will fuel the injectable route of administration. Biologics offer improved clinical advantage over conventional topical treatments since they target inflammatory mechanisms with disease modifying ability.
Discontinuation or termination of key pipeline candidates on account of unsuccessful clinical trials is a major restraint this market faces. Upon launch, Olumacostat glasaretil (Dermira; topical lipid synthesis inhibitor) was expected to be the first topical anti-acne drug with isotretinoin-like results without significant side effects. However, the drug failed to meet clinical endpoints, leading to discontinuation in March 2018. Similarly, SNA-001 (Sienna; silver nanoparticles solution) was deemed unsuccessful in two key trials wherein it was tested in conjunction with 810nm and 1064nm lasers in July 2018. Thesan withdrew TSN2898 from Phase II trials due to drug unavailability. Xenon discontinued development of XEN801 after the drug failed Phase II clinical trials.
Despite being one of the most common dermatological diseases in the world, innovation in acne treatment has been rather limited over the past decade. Drug companies are currently exploring novel treatment approaches including stearoyl CoA desaturase inhibition, melanocortin receptor antagonism, and anti-IL-1 monoclonal antibodies. Impending launch of late-stage pipeline products indicate a promising future for the global acne drugs market.
Some of the prominent players in the Acne Drugs Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Acne Drugs market.
By Type
By Therapeutic Class
By Mode of Administration
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Acne Drugs Market
5.1. COVID-19 Landscape: Acne Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Acne Drugs Market, By Type
8.1. Acne Drugs Market, by Type, 2023-2032
8.1.1 Comedonal
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Inflammatory
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Cystic
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Postsurgical/wound
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Acne Drugs Market, By Therapeutic Class
9.1. Acne Drugs Market, by Therapeutic Class, 2023-2032
9.1.1. Retinoid
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Antibiotic
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Hormonal Agent
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Combination
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Acne Drugs Market, By Mode of Administration
10.1. Acne Drugs Market, by Mode of Administration, 2023-2032
10.1.1. Topical
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Oral
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Injectable
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Acne Drugs Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.1.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.2.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.3.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.4.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.5.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Therapeutic Class (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Mode of Administration (2020-2032)
Chapter 12. Company Profiles
12.1. Allergan Plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AndroScience
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Anterios
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Aqua Pharmaceuticals
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer HealthCare
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Cipher Pharmaceuticals
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Galderma S.A
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. GlaxoSmithKline Plc (Stiefel Laboratories, Inc.)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Johnson & Johnson
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Mayne Pharma Group Limited
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers